Optimization and comparison of [¹⁸F]FET synthesis on two distinct automated radiochemistry systems.

IF 1.8 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

American journal of nuclear medicine and molecular imaging Pub Date : 2025-08-15 eCollection Date: 2025-01-01 DOI:10.62347/SPOE8395

Qi-Huang Zheng, Min Wang, Barbara E Glick-Wilson, Chase A Arkins, Eric R Klueppelberg, Scott E Snyder, Michael L Schulte

{"title":"Optimization and comparison of [18F]FET synthesis on two distinct automated radiochemistry systems.","authors":"Qi-Huang Zheng, Min Wang, Barbara E Glick-Wilson, Chase A Arkins, Eric R Klueppelberg, Scott E Snyder, Michael L Schulte","doi":"10.62347/SPOE8395","DOIUrl":null,"url":null,"abstract":"O-(2-[18F]Fluoroethyl)- L -tyrosine ([18F]FET) is a promising amino acid PET tracer for assessment of malignant brain tumors. Herein, we report optimized production of [18F]FET for clinical use on two commercial radiochemistry systems: Sofie ELIXYS and GE FASTlab 2. While the Sofie ELIXYS procedure requires high performance liquid chromatography (HPLC) purification, the GE FASTlab 2 method uses solid-phase extraction (SPE) purification. In both cases, [18F]FET met release specifications for clinical investigation laid out in the United States Pharmacopeia (USP) and/or European Pharmacopeia (Ph. Eur.). The radiochemical yield of [18F]FET was 35-55% and 30-55% decay corrected to start of synthesis (SOS) for Sofie ELIXYS and GE FASTlab 2, respectively. The overall synthesis time was 75-85 and 70-80 min from SOS for Sofie ELIXYS and GE FASTlab 2, respectively. The radiochemical purity was > 99%, and the molar activity (Am) was 340-464 GBq/µmol at end of synthesis (EOS).","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"15 4","pages":"158-166"},"PeriodicalIF":1.8000,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12444399/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of nuclear medicine and molecular imaging","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.62347/SPOE8395","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

O-(2-[¹⁸F]Fluoroethyl)- _L -tyrosine ([¹⁸F]FET) is a promising amino acid PET tracer for assessment of malignant brain tumors. Herein, we report optimized production of [¹⁸F]FET for clinical use on two commercial radiochemistry systems: Sofie ELIXYS and GE FASTlab 2. While the Sofie ELIXYS procedure requires high performance liquid chromatography (HPLC) purification, the GE FASTlab 2 method uses solid-phase extraction (SPE) purification. In both cases, [¹⁸F]FET met release specifications for clinical investigation laid out in the United States Pharmacopeia (USP) and/or European Pharmacopeia (Ph. Eur.). The radiochemical yield of [¹⁸F]FET was 35-55% and 30-55% decay corrected to start of synthesis (SOS) for Sofie ELIXYS and GE FASTlab 2, respectively. The overall synthesis time was 75-85 and 70-80 min from SOS for Sofie ELIXYS and GE FASTlab 2, respectively. The radiochemical purity was > 99%, and the molar activity (A_m) was 340-464 GBq/µmol at end of synthesis (EOS).

查看原文本刊更多论文

两种不同自动化放射化学系统上[18F]场效应管合成的优化与比较。

O-（2-[18F]氟乙基）- L -酪氨酸（[18F]FET）是一种很有前途的用于恶性脑肿瘤评估的氨基酸PET示踪剂。在此，我们报告了两种商用放射化学系统（Sofie ELIXYS和GE FASTlab 2）上用于临床使用的[18F]场效应管的优化生产。而Sofie ELIXYS程序需要高效液相色谱（HPLC）纯化，GE FASTlab 2方法使用固相萃取（SPE）纯化。在这两种情况下，[18F]FET都符合美国药典（USP）和/或欧洲药典（Ph. Eur.）中规定的临床研究放行规范。Sofie ELIXYS和GE FASTlab 2的[18F]FET的放射化学产率分别为35-55%和30-55%，衰变校正为合成开始（SOS）。Sofie ELIXYS和GE FASTlab 2的合成时间分别为75-85 min和70-80 min。放射化学纯度为bb0 99%，合成结束时摩尔活性（Am）为340-464 GBq/µmol （EOS）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American journal of nuclear medicine and molecular imaging RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-

自引率

4.00%

发文量

期刊介绍： The scope of AJNMMI encompasses all areas of molecular imaging, including but not limited to: positron emission tomography (PET), single-photon emission computed tomography (SPECT), molecular magnetic resonance imaging, magnetic resonance spectroscopy, optical bioluminescence, optical fluorescence, targeted ultrasound, photoacoustic imaging, etc. AJNMMI welcomes original and review articles on both clinical investigation and preclinical research. Occasionally, special topic issues, short communications, editorials, and invited perspectives will also be published. Manuscripts, including figures and tables, must be original and not under consideration by another journal.